Lupin
Lupin Limited, commonly referred to as Lupin, is a prominent global player in the pharmaceutical industry, headquartered in Mumbai, India. Founded in 1968, the company has established a strong presence in key operational regions, including North America, Europe, and Asia. Lupin is renowned for its diverse portfolio, which encompasses generic and branded formulations, biotechnology products, and active pharmaceutical ingredients (APIs). With a commitment to innovation, Lupin has achieved significant milestones, including numerous approvals from regulatory authorities worldwide. The company is particularly noted for its leadership in the anti-TB and cardiovascular segments, offering unique products that cater to unmet medical needs. As a result, Lupin has secured a competitive market position, consistently ranking among the top generic pharmaceutical companies globally.
DitchCarbon Score
How does Lupin's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Lupin's score of 51 is higher than 68% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Lupin's reported carbon emissions
In 2024, Lupin reported total greenhouse gas emissions of approximately 1,261,260,000 kg CO2e, comprising 61,474,000 kg CO2e from Scope 1, 263,905,000 kg CO2e from Scope 2, and 901,520,000 kg CO2e from Scope 3 emissions. This represents a significant increase in emissions compared to 2023, where total emissions were about 1,247,036,000 kg CO2e, with Scope 1 at 86,910,000 kg CO2e, Scope 2 at 323,845,000 kg CO2e, and Scope 3 at 854,936,000 kg CO2e. Lupin has set an ambitious target to reduce its Scope 1 and Scope 2 greenhouse gas emissions by 15% by 2030, starting from a baseline year of 2021. This commitment reflects the company's proactive approach to addressing climate change within the pharmaceutical sector. Additionally, Lupin is a signatory of the Climate Pledge, demonstrating its commitment to achieving net-zero emissions. The emissions data is not cascaded from any parent organization, indicating that Lupin is independently reporting its climate impact. The company continues to focus on sustainability initiatives as part of its broader corporate responsibility strategy.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Scope 1 | 103,887,000 | 000,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 371,883,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | 680,968,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Lupin is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
